Knight Therapeutics Inc T.GUD

Demand for innovative Biopharma companies fr big co.’s

[GoldenInvestor]

Turning Point Therapeutics (TPTX) – The biopharmaceutical company’s shares more than doubled in premarket trading after agreeing to be acquired by Bristol Myers Squibb (BMY) for $76 per share in cash, or $4.1 billion. Turning Point specializes in cancer treatments.

 

[GoldenInvestor]

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. It develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet

[MrMugsy]

Agreed Golden - there are a growing number of reasons why Big Pharma needs to make big moves over the next few years. For example ... Bristol has a few drugs that will come off patent before 2030. 1.  Revlimid (2026) - $12.1B in revenue will be targeted by generics 2.  Eliquis (2029) - $9.2B will be targeted by generics (this is a partnership with Pfizer) 3.  Opdivo (2028) - $7.0B

[GoldenInvestor]

Thanks for the detailed insight! Better Lucky than Smart!         (- a quote from our Executive Director/founder) GUD times ahead!!